TITLE

CIMA LABS GETS MICROEMULSION ORAL DRUG DELIVERY PATENT

PUB. DATE
November 2001
SOURCE
Biotech Business;Nov2001, Vol. 14 Issue 11, p2
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the patent issued by the United States Patent and Trademark office for a drug delivery technology of CIMA LABS Inc.
ACCESSION #
5524656

 

Related Articles

  • ORGANON GETS FIRST EUROPEAN MARKETING APPROVAL FOR REMERON.  // Worldwide Biotech;Sep2001, Vol. 13 Issue 9, p2 

    No abstract available.

  • Impax Laboratories initiates patent challenge relating to Generic Fentora.  // PharmaWatch: CNS;Jan2012, Vol. 11 Issue 1, p14 

    The article reports that Cephalon Inc. and CIMA Labs Inc. have filed a lawsuit against Impax Laboratories Inc. on November 18, 2011 for patent infringement with regards to the company's Fentora or fentanyl buccal tablets.

  • CIMA/aaiPharma Tie the Pharmaceutical Knot.  // High Yield Report;8/11/2003, Vol. 14 Issue 32, p1 

    Reports on the proposed merger between U.S.-based pharmaceutical companies aaiPharma and CIMA. Impact of the proposed merger on the financial conditions of the drug manufacturing industry; Estimated capital of the merged companies; Financial standings of the two pharmaceutical companies.

  • Hardball Over a Breakup Fee. Sikora, Martin // Mergers & Acquisitions: The Dealermaker's Journal;Sep2004, Vol. 39 Issue 9, p3 

    Reflects on the lawsuit filed by CIMA Labs Inc. against aaiPharma Inc. for fraud and breach of contract. Demands of CIMA; Issues behind the lawsuit filed by CIMA; Effect of breakup fee on the bidding process.

  • Pharma says acquisition is the right prescription. Speizer, Irwin // Business North Carolina;Oct2003, Vol. 23 Issue 10, p22 

    Reports on the merger of drug company aaiPharma Inc. with Cima Labs Inc. in 2003. Basis of the consolidation; Impact of the merger on the companies' stock performance; Changes after the merger.

  • Cima Leaves aaiPharma for Cephalon.  // Chemical Market Reporter;11/10/2003, Vol. 264 Issue 16, p2 

    Reports on the ownership and control of the drug delivery technology platform, Cima Labs Inc. won by drug company, Cephalon Inc. over aaiPharma Inc. Terms and details of the stock purchase; Operations and financial performance of the companies; Stock price.

  • aaiPharma to acquire rival Cima Labs.  // PharmaWatch: CNS;September 2003, Vol. 2 Issue 9, p19 

    Reports on the intention of aaiPharma Inc. to acquire Cima Labs Inc. Terms under the deal; Benefits of the agreement for both companies; Significance of the deal for the pharmaceutical biotechnology industry.

  • Pharmaceuticals firm to bring up to 85 new jobs to Salt Lake City. Shelton, Ryan // Enterprise/Salt Lake City;6/1/2009, Vol. 38 Issue 49, p1 

    The article reports on the decision of Cephalon Inc., a pharmaceutical company based in Frazer, Pennsylvania, to relocate its subsidiary, CIMA Labs in Brooklyn Park, Minnesota to Salt Lake City, Utah. In line with the planned relocation, Cephalon has commenced the construction of the facility...

  • Cephalon Maintains CIMA Takeout Will Fly. Cohen, Judy Radler // Mergers & Acquisitions Report;4/12/2004, Vol. 17 Issue 15, p1 

    Discusses the status of the acquisition deal between Cephalon Inc. and CIMA Laboratories Inc. Amount of money involved in the deal; Tender offer of Cephalon Inc. for the shares of CIMA; Information on the two fentanyl products from CIMA Laboratories Inc. that Cephalon Inc. wants to acquire;...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics